Lupin Launches Lurasidone Hydrochloride Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, to market a generic equivalent of Latuda® Tablets of Sunovion Pharmaceuticals, Inc.

Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (RLD Latuda®) had estimated annual sales of USD 4.2 billion in the U.S. (IQVIA MAT December 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 666.85 as compared to the previous close of Rs. 670.05. The total number of shares traded during the day was 20651 in over 1231 trades.

The stock hit an intraday high of Rs. 674.70 and intraday low of 658.90. The net turnover during the day was Rs. 13771630.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 LurasidoneHydrochlorideTablets Generic